JP2021522786A5 - - Google Patents
Info
- Publication number
- JP2021522786A5 JP2021522786A5 JP2020560958A JP2020560958A JP2021522786A5 JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5 JP 2020560958 A JP2020560958 A JP 2020560958A JP 2020560958 A JP2020560958 A JP 2020560958A JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- structural unit
- subunit
- linker segment
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025082038A JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810420739.6A CN110437339B (zh) | 2018-05-04 | 2018-05-04 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| CN201810420739.6 | 2018-05-04 | ||
| PCT/US2019/030594 WO2019213517A1 (en) | 2018-05-04 | 2019-05-03 | Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082038A Division JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522786A JP2021522786A (ja) | 2021-09-02 |
| JP2021522786A5 true JP2021522786A5 (enExample) | 2022-05-13 |
| JP7684047B2 JP7684047B2 (ja) | 2025-05-27 |
Family
ID=68386875
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560958A Active JP7684047B2 (ja) | 2018-05-04 | 2019-05-03 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
| JP2025082038A Pending JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082038A Pending JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12441781B2 (enExample) |
| EP (1) | EP3788068A4 (enExample) |
| JP (2) | JP7684047B2 (enExample) |
| KR (1) | KR20210028150A (enExample) |
| CN (4) | CN110437339B (enExample) |
| AU (1) | AU2019262590B2 (enExample) |
| CA (1) | CA3099039A1 (enExample) |
| WO (1) | WO2019213517A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| CN111100211B (zh) * | 2019-01-30 | 2022-04-08 | 武汉九州钰民医药科技有限公司 | 一种Fc融合蛋白及其应用 |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2021113577A1 (en) * | 2019-12-05 | 2021-06-10 | Immune Targeting Inc. | Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| CN115151644B (zh) * | 2019-12-27 | 2024-06-21 | 国立大学法人神户大学 | 癌基因治疗药 |
| WO2021142476A1 (en) * | 2020-01-12 | 2021-07-15 | Dragonfly Therapeutics, Inc. | Single-chain polypeptides |
| CN113321738A (zh) * | 2020-02-27 | 2021-08-31 | 启愈生物技术(上海)有限公司 | 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用 |
| WO2021188835A1 (en) * | 2020-03-18 | 2021-09-23 | City Of Hope | Multivalent chemokine receptor binding complexes |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| CN114057889B (zh) * | 2020-07-30 | 2023-11-10 | 深圳市北科生物科技有限公司 | 二硫键稳定的IL15-IL15Rα复合物及其应用 |
| WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
| JP2023540629A (ja) * | 2020-09-16 | 2023-09-25 | ベイジーン リミテッド | インターロイキン１５構築物及び使用方法 |
| CN118598976A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| WO2022216993A2 (en) * | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| CN113321740B (zh) * | 2021-05-08 | 2023-07-18 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| CN113817072B (zh) * | 2021-10-28 | 2024-02-20 | 苏州生物医药转化工程中心 | 一种白细胞介素15及其受体-单克隆抗体融合蛋白的纯化贮存方法 |
| CA3238283A1 (en) * | 2021-11-15 | 2023-05-19 | Yangxin Fu | Fusion protein construct taking interleukin 15 as active ingredient and use thereof |
| JP2025507733A (ja) * | 2022-02-28 | 2025-03-21 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用 |
| CN119790066A (zh) * | 2022-08-05 | 2025-04-08 | 舒泰神(加州)生物科技有限公司 | 一种新型IL-15R alpha Fc融合蛋白及其使用 |
| KR20250135294A (ko) * | 2023-02-21 | 2025-09-12 | 레메젠 코, 리미티드 | 암을 위한 il-15 작용제 |
| WO2024230591A1 (zh) * | 2023-05-06 | 2024-11-14 | 北京新合睿恩生物医疗科技有限公司 | IL-15融合蛋白及其mRNA序列和应用 |
| CN116554356B (zh) * | 2023-05-16 | 2024-01-23 | 武汉大学 | 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用 |
| WO2025129454A1 (zh) * | 2023-12-19 | 2025-06-26 | 中国科学院生物物理研究所 | Il-15与t细胞共刺激分子抗体构成的双功能融合蛋白 |
| WO2026006679A1 (en) * | 2024-06-28 | 2026-01-02 | The Regents Of The University Of California | Retroviral vectors |
| WO2026037415A1 (zh) * | 2024-08-16 | 2026-02-19 | 北京清辉联诺生物科技有限责任公司 | 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063974A2 (en) | 2004-12-13 | 2006-06-22 | Cytos Biotechnology Ag | Il-15 antigen arrays and uses thereof |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US8507222B2 (en) * | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| EP2915569A1 (en) * | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| PL3235830T3 (pl) * | 2014-12-19 | 2020-12-14 | Jiangsu Hengrui Medicine Co., Ltd. | Kompleks białkowy interleukiny 15 i jego zastosowanie |
| CN112574316A (zh) * | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| JP2018532729A (ja) | 2015-09-25 | 2018-11-08 | アルター・バイオサイエンス・コーポレーション | インターロイキン−１５スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
-
2018
- 2018-05-04 CN CN201810420739.6A patent/CN110437339B/zh active Active
-
2019
- 2019-05-03 EP EP19796151.9A patent/EP3788068A4/en active Pending
- 2019-05-03 US US17/051,160 patent/US12441781B2/en active Active
- 2019-05-03 CA CA3099039A patent/CA3099039A1/en active Pending
- 2019-05-03 CN CN202510533077.3A patent/CN120463817A/zh active Pending
- 2019-05-03 JP JP2020560958A patent/JP7684047B2/ja active Active
- 2019-05-03 CN CN201980045118.7A patent/CN112585161B/zh active Active
- 2019-05-03 AU AU2019262590A patent/AU2019262590B2/en active Active
- 2019-05-03 CN CN202510533066.5A patent/CN120463816A/zh active Pending
- 2019-05-03 KR KR1020207034734A patent/KR20210028150A/ko active Pending
- 2019-05-03 WO PCT/US2019/030594 patent/WO2019213517A1/en not_active Ceased
-
2025
- 2025-05-15 JP JP2025082038A patent/JP2025124695A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522786A5 (enExample) | ||
| JP2025032113A5 (enExample) | ||
| JP2021521822A5 (enExample) | ||
| EP3844181B1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| EP3844182B1 (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
| JP7413338B2 (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| JP2022169543A (ja) | 改善された養子ｔ細胞療法 | |
| KR102669749B1 (ko) | 키메라 사이토카인 수용체 | |
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| US12479899B2 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| JP2023503868A5 (enExample) | ||
| Karches et al. | Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy | |
| US20180312570A1 (en) | Receptor | |
| JP2023518443A5 (enExample) | ||
| AU2017357649A1 (en) | Chimeric antigen receptor | |
| WO2021032116A1 (zh) | 一种免疫细胞因子及其制备与用途 | |
| JP2023551481A5 (enExample) | ||
| CN112601546A (zh) | Plap-car-效应细胞 | |
| Lo et al. | Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP2023503840A5 (enExample) | ||
| CN110903402A (zh) | 一种双特异性融合蛋白及其构建方法与应用 | |
| JP2023540022A5 (enExample) | ||
| JP2023540023A5 (enExample) |